XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Deficit
Accumulated Other Comprehensive Loss
Treasury Stock
Beginning balance (in shares) at Dec. 31, 2022   20,631,000        
Beginning balance at Dec. 31, 2022 $ 158,438 $ 206 $ 160,475 $ 13,718 $ (4,110) $ (11,851)
Beginning balance, treasury stock (in shares) at Dec. 31, 2022           (1,433,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income 1,140     1,140    
Other comprehensive (loss) income 155 [1]       155  
Stock-based compensation 874   874      
Acquisition of treasury stock (in shares)           (23,000)
Acquisition of treasury stock (239)         $ (239)
Exercise of stock options and issuance of restricted stock awards, net of forfeitures (in shares)   338,000        
Exercise of stock options and issuance of restricted stock awards, net of forfeitures 2,345 $ 4 2,341      
Ending balance (in shares) at Jun. 30, 2023   20,969,000        
Ending balance at Jun. 30, 2023 162,713 $ 210 163,690 14,858 (3,955) $ (12,090)
Ending balance, treasury stock (in shares) at Jun. 30, 2023           (1,456,000)
Beginning balance (in shares) at Mar. 31, 2023   20,826,000        
Beginning balance at Mar. 31, 2023 159,951 $ 208 161,779 14,085 (4,031) $ (12,090)
Beginning balance, treasury stock (in shares) at Mar. 31, 2023           (1,456,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income 773     773    
Other comprehensive (loss) income 76 [1]       76  
Stock-based compensation 578   578      
Exercise of stock options and issuance of restricted stock awards, net of forfeitures (in shares)   143,000        
Exercise of stock options and issuance of restricted stock awards, net of forfeitures 1,335 $ 2 1,333      
Ending balance (in shares) at Jun. 30, 2023   20,969,000        
Ending balance at Jun. 30, 2023 $ 162,713 $ 210 163,690 14,858 (3,955) $ (12,090)
Ending balance, treasury stock (in shares) at Jun. 30, 2023           (1,456,000)
Beginning balance (in shares) at Dec. 31, 2023 19,610,790 21,067,000        
Beginning balance at Dec. 31, 2023 $ 147,372 $ 211 165,140 (1,704) (4,185) $ (12,090)
Beginning balance, treasury stock (in shares) at Dec. 31, 2023 (1,456,109)         (1,456,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income $ (5,539)     (5,539)    
Other comprehensive (loss) income 194 [1]       194  
Stock-based compensation 1,244   1,244      
Issuance of common stock under employee stock purchase plan (in shares)   24,000        
Issuance of common stock under employee stock purchase plan 95   95      
Exercise of stock options and issuance of restricted stock awards, net of forfeitures (in shares)   79,000        
Exercise of stock options and issuance of restricted stock awards, net of forfeitures $ 12 $ 1 11      
Ending balance (in shares) at Jun. 30, 2024 19,714,086 21,170,000        
Ending balance at Jun. 30, 2024 $ 143,378 $ 212 166,490 (7,243) (3,991) $ (12,090)
Ending balance, treasury stock (in shares) at Jun. 30, 2024 (1,456,109)         (1,456,000)
Beginning balance (in shares) at Mar. 31, 2024   21,205,000        
Beginning balance at Mar. 31, 2024 $ 145,067 $ 212 165,768 (4,867) (3,956) $ (12,090)
Beginning balance, treasury stock (in shares) at Mar. 31, 2024           (1,456,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net (loss) income (2,376)     (2,376)    
Other comprehensive (loss) income (35) [1]       (35)  
Stock-based compensation $ 722   722      
Exercise of stock options and issuance of restricted stock awards, net of forfeitures (in shares)   (35,000)        
Ending balance (in shares) at Jun. 30, 2024 19,714,086 21,170,000        
Ending balance at Jun. 30, 2024 $ 143,378 $ 212 $ 166,490 $ (7,243) $ (3,991) $ (12,090)
Ending balance, treasury stock (in shares) at Jun. 30, 2024 (1,456,109)         (1,456,000)
[1] Tax impact was nominal for all periods.